Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.53-0.10 (-1.78%)
At close: 4:00PM EDT
5.53 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.63
Open5.73
Bid5.37 x 900
Ask6.10 x 800
Day's Range5.48 - 5.76
52 Week Range4.80 - 20.29
Volume223,742
Avg. Volume675,661
Market Cap204.023M
Beta (5Y Monthly)0.03
PE Ratio (TTM)N/A
EPS (TTM)-6.36
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.67
  • GlobeNewswire

    Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2021 Annual Meeting, which is being held November 10-14, 2021 in Washington, D.C. Details are as follows: Title: First-in-Human Results with the Novel Tumor-Targeting An

  • GlobeNewswire

    Atreca to Present at Upcoming Virtual Investor Conferences

    SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences: HC Wainwright 23rd Annual Global Investment ConferenceSeptember 13-15, 2021Presentation available beginning September 13 Baird G

  • GlobeNewswire

    Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

    SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments. “We recently announced initial summary data from the dose escalation portion of the Phase 1b tr

Advertisement
Advertisement